Multi-omics analyses detail metabolic reprogramming in lipids, carnitines, and use of glycolytic intermediates between prostate small cell neuroendocrine carcinoma and prostate adenocarcinoma

Bei Gao, Hui Wen Lue, Jennifer Podolak, Sili Fan, Ying Zhang, Archana Serawat, Joshi Alumkal, Oliver Fiehn, George Thomas

Research output: Contribution to journalArticle

Abstract

As the most common cancer in men, prostate cancer is molecularly heterogeneous. Contributing to this heterogeneity are the poorly understood metabolic adaptations of the two main types of prostate cancer, i.e., adenocarcinoma and small cell neuroendocrine carcinoma (SCNC), the latter being more aggressive and lethal. Using transcriptomics, untargeted metabolomics and lipidomics profiling on LASCPC-01 (prostate SCNC) and LNCAP (prostate adenocarcinoma) cell lines, we found significant differences in the cellular phenotypes of the two cell lines. Gene set enrichment analysis on the transcriptomics data showed 62 gene sets were upregulated in LASCPC-01, while 112 gene sets were upregulated in LNCAP. ChemRICH analysis on metabolomics and lipidomics data revealed a total of 25 metabolite clusters were significantly different. LASCPC-01 exhibited a higher glycolytic activity and lower levels of triglycerides, while the LNCAP cell line showed increases in one-carbon metabolism as an exit route of glycolytic intermediates and a decrease in carnitine, a mitochondrial lipid transporter. Our findings pinpoint differences in prostate neuroendocrine carcinoma versus prostate adenocarcinoma that could lead to new therapeutic targets in each type.

Original languageEnglish (US)
Article number82
JournalMetabolites
Volume9
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Neuroendocrine Carcinoma
Small Cell Carcinoma
Carnitine
Prostate
Adenocarcinoma
Genes
Cells
Lipids
Metabolomics
Cell Line
Prostatic Neoplasms
Metabolites
Metabolism
Triglycerides
Carbon
Phenotype
Neoplasms
Therapeutics

Keywords

  • Extracellular acidification rate
  • Hydrophilic interaction liquid chromatography (HILIC)
  • N-Myc
  • Oxygen consumption rate

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology

Cite this

Multi-omics analyses detail metabolic reprogramming in lipids, carnitines, and use of glycolytic intermediates between prostate small cell neuroendocrine carcinoma and prostate adenocarcinoma. / Gao, Bei; Lue, Hui Wen; Podolak, Jennifer; Fan, Sili; Zhang, Ying; Serawat, Archana; Alumkal, Joshi; Fiehn, Oliver; Thomas, George.

In: Metabolites, Vol. 9, No. 5, 82, 01.05.2019.

Research output: Contribution to journalArticle

@article{75f02e6ff60f40088d97a14c43e5ea83,
title = "Multi-omics analyses detail metabolic reprogramming in lipids, carnitines, and use of glycolytic intermediates between prostate small cell neuroendocrine carcinoma and prostate adenocarcinoma",
abstract = "As the most common cancer in men, prostate cancer is molecularly heterogeneous. Contributing to this heterogeneity are the poorly understood metabolic adaptations of the two main types of prostate cancer, i.e., adenocarcinoma and small cell neuroendocrine carcinoma (SCNC), the latter being more aggressive and lethal. Using transcriptomics, untargeted metabolomics and lipidomics profiling on LASCPC-01 (prostate SCNC) and LNCAP (prostate adenocarcinoma) cell lines, we found significant differences in the cellular phenotypes of the two cell lines. Gene set enrichment analysis on the transcriptomics data showed 62 gene sets were upregulated in LASCPC-01, while 112 gene sets were upregulated in LNCAP. ChemRICH analysis on metabolomics and lipidomics data revealed a total of 25 metabolite clusters were significantly different. LASCPC-01 exhibited a higher glycolytic activity and lower levels of triglycerides, while the LNCAP cell line showed increases in one-carbon metabolism as an exit route of glycolytic intermediates and a decrease in carnitine, a mitochondrial lipid transporter. Our findings pinpoint differences in prostate neuroendocrine carcinoma versus prostate adenocarcinoma that could lead to new therapeutic targets in each type.",
keywords = "Extracellular acidification rate, Hydrophilic interaction liquid chromatography (HILIC), N-Myc, Oxygen consumption rate",
author = "Bei Gao and Lue, {Hui Wen} and Jennifer Podolak and Sili Fan and Ying Zhang and Archana Serawat and Joshi Alumkal and Oliver Fiehn and George Thomas",
year = "2019",
month = "5",
day = "1",
doi = "10.3390/metabo9050082",
language = "English (US)",
volume = "9",
journal = "Metabolites",
issn = "2218-1989",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - Multi-omics analyses detail metabolic reprogramming in lipids, carnitines, and use of glycolytic intermediates between prostate small cell neuroendocrine carcinoma and prostate adenocarcinoma

AU - Gao, Bei

AU - Lue, Hui Wen

AU - Podolak, Jennifer

AU - Fan, Sili

AU - Zhang, Ying

AU - Serawat, Archana

AU - Alumkal, Joshi

AU - Fiehn, Oliver

AU - Thomas, George

PY - 2019/5/1

Y1 - 2019/5/1

N2 - As the most common cancer in men, prostate cancer is molecularly heterogeneous. Contributing to this heterogeneity are the poorly understood metabolic adaptations of the two main types of prostate cancer, i.e., adenocarcinoma and small cell neuroendocrine carcinoma (SCNC), the latter being more aggressive and lethal. Using transcriptomics, untargeted metabolomics and lipidomics profiling on LASCPC-01 (prostate SCNC) and LNCAP (prostate adenocarcinoma) cell lines, we found significant differences in the cellular phenotypes of the two cell lines. Gene set enrichment analysis on the transcriptomics data showed 62 gene sets were upregulated in LASCPC-01, while 112 gene sets were upregulated in LNCAP. ChemRICH analysis on metabolomics and lipidomics data revealed a total of 25 metabolite clusters were significantly different. LASCPC-01 exhibited a higher glycolytic activity and lower levels of triglycerides, while the LNCAP cell line showed increases in one-carbon metabolism as an exit route of glycolytic intermediates and a decrease in carnitine, a mitochondrial lipid transporter. Our findings pinpoint differences in prostate neuroendocrine carcinoma versus prostate adenocarcinoma that could lead to new therapeutic targets in each type.

AB - As the most common cancer in men, prostate cancer is molecularly heterogeneous. Contributing to this heterogeneity are the poorly understood metabolic adaptations of the two main types of prostate cancer, i.e., adenocarcinoma and small cell neuroendocrine carcinoma (SCNC), the latter being more aggressive and lethal. Using transcriptomics, untargeted metabolomics and lipidomics profiling on LASCPC-01 (prostate SCNC) and LNCAP (prostate adenocarcinoma) cell lines, we found significant differences in the cellular phenotypes of the two cell lines. Gene set enrichment analysis on the transcriptomics data showed 62 gene sets were upregulated in LASCPC-01, while 112 gene sets were upregulated in LNCAP. ChemRICH analysis on metabolomics and lipidomics data revealed a total of 25 metabolite clusters were significantly different. LASCPC-01 exhibited a higher glycolytic activity and lower levels of triglycerides, while the LNCAP cell line showed increases in one-carbon metabolism as an exit route of glycolytic intermediates and a decrease in carnitine, a mitochondrial lipid transporter. Our findings pinpoint differences in prostate neuroendocrine carcinoma versus prostate adenocarcinoma that could lead to new therapeutic targets in each type.

KW - Extracellular acidification rate

KW - Hydrophilic interaction liquid chromatography (HILIC)

KW - N-Myc

KW - Oxygen consumption rate

UR - http://www.scopus.com/inward/record.url?scp=85068548612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068548612&partnerID=8YFLogxK

U2 - 10.3390/metabo9050082

DO - 10.3390/metabo9050082

M3 - Article

AN - SCOPUS:85068548612

VL - 9

JO - Metabolites

JF - Metabolites

SN - 2218-1989

IS - 5

M1 - 82

ER -